Physician profile
Reve Shields
NPI 1871719187
$2,034.30
in general payments reported to CMS, 2019-2025
23 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $82.67 · 2023: $303 · 2024: $496 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $241.15 | 2023-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $163.30 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $162.00 | 2023-2025 | |
| Eisai INC. | $141.87 | 2024-2025 | |
| Genentech USA, INC. | $135.32 | 2024-2025 | Polivy, Phesgo |
| Genzyme Corporation | $133.84 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.71 | 2023-2025 | Epanova, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $114.85 | 2022-2025 | Keytruda, Keytruda Qlex |
| Astellas Pharma US INC | $95.00 | 2021 | |
| Janssen Biotech, INC. | $91.37 | 2025 | Erleada, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $78.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $76.41 | 2024-2025 | Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $69.09 | 2023 | Reblozyl |
| Lilly USA, LLC | $62.56 | 2024-2025 | Verzenio, Jaypirca |
| Agios Pharmaceuticals, INC. | $48.70 | 2025 | Pyrukynd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $48.45 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Seagen INC. | $46.46 | 2023 | Adcetris |
| Abbvie INC. | $43.58 | 2025 | |
| Beone Medicines USA, INC. | $38.97 | 2025 | Brukinsa, Tevimbra |
| Amgen INC. | $35.98 | 2023 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $30.40 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $23.79 | 2023 | Krazati |
| Daiichi Sankyo INC. | $23.78 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reve Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.